-
Start Preamble
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis Panel; Omnibus R03 & R21 SEP-2.
Date: September 15-16, 2014.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW., Washington, DC 20015.
Contact Person: Eun Ah Cho, Ph.D., Scientific Review Officer and Acting Chief, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W106, Bethesda, MD 20892-9750, 240-276-6342, choe@mail.nih.gov.
Name of Committee: National Cancer Institute Initial Review Group; Subcommittee I—Transition to Independence.
Date: November 4-5, 2014.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda One Bethesda Metro Center Bethesda, MD 20814.
Contact Person: Sergei Radaev, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W634, Bethesda, MD 20892-9750, 240-276-6466, sradaev@mail.nih.gov.
Information is also available on the Institute's/Center's home page: http://deainfo.nci.nih.gov/advisory/sep/sep.htm,, where an agenda and any additional information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Start SignatureDated: August 6, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-18996 Filed 8-11-14; 8:45 am]
BILLING CODE 4140-01-P
Document Information
- Effective Date:
- 9/15/2014
- Published:
- 08/12/2014
- Department:
- National Institutes of Health
- Entry Type:
- Notice
- Document Number:
- 2014-18996
- Dates:
- September 15-16, 2014.
- Pages:
- 47149-47149 (1 pages)
- PDF File:
- 2014-18996.pdf
- Supporting Documents:
- » License Agreements; Start-Up Exclusive Evaluation Option: Activators of Human Pyruvate Kinase to Treat Cancer
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: National Institute of Nursing Research
- » Meetings: National Institute of Allergy and Infectious Diseases
- » Meetings: National Eye Institute
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: Center for Scientific Review
- » Meetings: Center for Scientific Review
- » Meetings: National Institute of Environmental Health Sciences
- » Meetings: National Human Genome Research Institute